<DOC>
	<DOCNO>NCT00471276</DOCNO>
	<brief_summary>Patients advance breast cancer receive sunitinib ( Sutent ) daily disease progression .</brief_summary>
	<brief_title>Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically cytologically proven diagnosis breast cancer Metastatic locally recurrent disease , opinion investigator , amenable resection radiation therapy Patients least one measurable lesion per RECIST Inflammatory breast cancer Prior treatment VEGF inhibitor ( unless adjuvant set least 12 month ago )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>